Davidson Investment Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Davidson Investment Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-185,917	Closed	-$20.3M	–	116
2023 Q1	$20.3M	Buy	185,917 +18,896	+11%	+$2.09M	1.33%	14
2022 Q4	$19M	Buy	167,021 +9,357	+6%	+$777K	1.48%	16
2022 Q3	$9.76M	Buy	+157,664	New	+$11M	0.82%	58
2017 Q3	–	Sell	-225	Closed	-$2K	–	198
2017 Q2	$2K	Hold	225	–	–	﹤0.01%	195
2017 Q1	$3K	Sell	225 -315	-58%	-$5.1K	﹤0.01%	197
2016 Q4	$8K	Hold	540	–	–	﹤0.01%	201
2016 Q3	$9K	Hold	540	–	–	﹤0.01%	189
2016 Q2	$8K	Sell	540 -16,470	-97%	-$266K	﹤0.01%	185
2016 Q1	$278K	Sell	17,010 -40,310	-70%	-$705K	0.05%	121
2015 Q4	$1.24M	Buy	57,320 +255	+0.4%	+$4.96K	0.21%	100
2015 Q3	$1.13M	Sell	57,065 -3,150	-5%	-$99.5K	0.2%	99
2015 Q2	$2.09M	Sell	60,215 -760	-1%	-$23.2K	0.31%	89
2015 Q1	$1.58M	Sell	60,975 -40,360	-40%	-$740K	0.24%	95
2014 Q4	$1.3M	Sell	101,335 -525	-0.5%	-$6.57K	0.2%	101
2014 Q3	$1.25M	Buy	+101,860	New	+$1.18M	0.1%	118

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Davidson Investment Advisors's HZNP Position: Q2 2023 in Review

Davidson Investment Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 185,917 shares — an estimated $20.3M sold.

Davidson Investment Advisors first reported a position in HZNP in Q3 2014 and held it in 15 quarters. The position peaked at $20.3M in Q1 2023. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Davidson Investment Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Davidson Investment Advisors sold 185,917 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $20.3M.
Davidson Investment Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2014 and held it in 15 quarters.
Davidson Investment Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $20.3M in Q1 2023.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Davidson Investment Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.